Cardio-oncology Training in the COVID-19 Era

Curr Treat Options Oncol. 2021 Jun 7;22(7):58. doi: 10.1007/s11864-021-00855-y.


Cardio-oncology is a field dedicated to the prevention, diagnosis, and management of cardiovascular disease in cancer patients before, during, and after cancer therapy. It is an emerging field with limited opportunities for structured education and training. In the year 2021, we cannot define the requirements of cardio-oncology training without acknowledging the impact of the global coronavirus disease 19 (COVID-19) pandemic. While this pandemic poses significant health risks to patients with cancer and cardiovascular disease as well as the providers who care for them, it also allows novel opportunities for the nascent field of cardio-oncology to readily adapt. In this article, we detail how the COVID-19 pandemic has impacted all aspects of cardio-oncology training, how programs and trainees can adapt to these challenges, and how lessons learned from the COVID-19 era can continue to positively impact cardio-oncology training for the foreseeable future.

Keywords: COVID-19; Cardio-oncology; Cardiotoxicity; Fellowship training; Medical education.

Publication types

  • Review

MeSH terms

  • COVID-19 / complications*
  • COVID-19 / virology
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / complications
  • Cardiovascular Diseases / prevention & control*
  • Cardiovascular Diseases / virology
  • Humans
  • Medical Oncology / trends
  • Neoplasms / complications
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Neoplasms / virology
  • SARS-CoV-2 / pathogenicity